BBR Partners’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

BBR Partners’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-61,649	Closed	-$142K	–	118
2018 Q2	$142K	Buy	+61,649	New	+$180K	0.02%	89

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

BBR Partners's OMED Position: Q3 2018 in Review

BBR Partners sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2018, closing a stake of 61,649 shares — an estimated $142K sold.

BBR Partners first reported a position in OMED in Q2 2018 and held it in 1 quarter. The position peaked at $142K in Q2 2018. 54 funds tracked by Wall St. Rank hold OMED as of Q3 2018.

BBR Partners reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
BBR Partners sold 61,649 OncoMed Pharmaceuticals, Inc. shares in Q3 2018, an estimated $142K.
BBR Partners first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
BBR Partners's OncoMed Pharmaceuticals, Inc. position peaked at $142K in Q2 2018.
54 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2018.

Based on BBR Partners's 13F filing for Q3 2018, filed 13 Nov 2018.